RVMD Pancreatic Data: Nextech's 58% Portfolio Bet Validated

Revolution Medicines disclosed preliminary data this week suggesting daraxonrasib, its pan-RAS(ON) inhibitor, may double overall survival in metastatic pancreatic cancer versus standard-of-care chemotherapy. The headline is a clinical milestone; for institutional readers, the more useful read sits in the 13F filings — specifically in how concentrated the smart-money ownership of RVMD already was before the data dropped.

This is not a name where the holder base is dominated by index flow. The active conviction stack on Revolution Medicines is one of the most concentrated on the entire smid-cap biotech tape, with multiple funds running the position at single-digit-plus portfolio weights and one specialist running it as a majority-of-book position. The clinical readout lands directly on a holder configuration that has been underwriting exactly this scenario.

The Conviction Holders Behind the RAS Bet

Pulled from the most recent quarter's 13F filings, the active institutions holding Revolution Medicines as a meaningful position sort into a remarkably tight list.

Filer	Reported Value	% of Portfolio	Report Date
Nextech Invest	$605.4M	58.53%	2025-12-31
Nextech Invest Ltd. (parallel)	$332.5M	53.94%	2025-12-31
Paradigm Biocapital Advisors	$529.2M	13.51%	2025-12-31
Alphabet Inc. (corporate)	$320.2M	7.97%	2025-12-31
Bellevue Group AG	$398.7M	7.56%	2025-12-31
Farallon Capital	$1.16B	5.48%	2025-12-31
Baker Bros. Advisors	$753.1M	4.41%	2025-12-31

Nextech is the line that earns the second read. The Zurich-based oncology specialist runs two related entities, both of which are more than half-invested in a single position — 58.53% and 53.94% of reported portfolios respectively. That is not a diversified biotech book with a tilt. That is a fund that has built itself around being right on RAS-pathway inhibition, and Revolution Medicines is the bet.

Paradigm Biocapital at 13.51% is in the same category — a specialist biotech allocator running RVMD as one of the firm's defining positions. Bellevue Group's 7.56% on a global healthcare-focused book carries the same flavor. Together with Baker Bros — the most recognizable name on the biotech specialist circuit — these funds form the conviction core that an FDA filing or a confirmatory Phase III readout would convert into a multi-bagger.

Why Alphabet and Farallon Matter Differently

Two names on the list above deserve a separate framing. Alphabet's $320 million RVMD stake is a corporate-treasury / strategic investment position, not a hedge fund bet. Alphabet's 13F filings show a small, concentrated portfolio of life-sciences names where Verily and the broader Google Ventures footprint have taken direct equity positions; RVMD at 7.97% of that portfolio means Alphabet's corporate team views Revolution Medicines as one of its most material strategic equity exposures.

Farallon Capital at $1.16 billion (5.48% portfolio weight) is the largest dollar position on the list but operates in a different lane — a multi-strategy hedge fund with deep healthcare event-driven expertise. Farallon at 5.48% of a $21 billion reported book signals an event-aware sizing into the daraxonrasib catalyst window, distinct from the long-term specialist conviction of Nextech and Paradigm.

What the Survival Data Actually Changes

Daraxonrasib (RMC-6236) targets the active, GTP-bound state of multiple RAS mutations — a mechanism that, if validated through registrational data, applies to roughly 25% of all solid tumors. The pancreatic cancer signal matters because PDAC is the highest-unmet-need solid tumor where standard of care (gemcitabine plus nab-paclitaxel, or FOLFIRINOX) produces overall survival in the 8-12 month range. Doubling that bar would qualify as one of the most material oncology readouts of the past decade.

For the holders above, three things shift with this announcement:

• RAS-platform validation: A positive pancreatic survival signal is the most credible read-through to KRAS G12C/G12D/G12V combinations across NSCLC, colorectal, and pancreatic adenocarcinoma. Nextech's portfolio weighting is built on this assumption.
• BD optionality: Strategic acquirers (Eli Lilly, AstraZeneca, Pfizer, Merck KGaA) have been watching the RAS-ON space for two cycles. A doubled-survival signal compresses the M&A timeline.
• Cash runway dynamics: RVMD's existing cash position carries the program into late-stage trials, but a confirmatory dataset opens the equity-financing window at a materially higher valuation.

The 13D/G and Insider Read

There are no recent 13D or 13G activist filings on Revolution Medicines, and no Form 4 stream suggesting the senior management team or board has shifted its own posture. The clinical readout lands on a holder base that has been positioning into the catalyst window — not one being repositioned by it.

The non-conviction inventory on the cap table — BlackRock, Vanguard, State Street, Geode — reflects pure index-mandate flow into the biotech XBI bucket and is not a read on the daraxonrasib data. Treating their presence as institutional endorsement of the RAS thesis misreads the filing taxonomy. The active read lives in the seven names above.

What to Watch From Here

Three anchored signals worth tracking through the next two reporting cycles:

• Q1 2026 13F filings (due May 15, 2026): Whether Nextech, Paradigm, or Bellevue trimmed into the run-up, or stayed full-weighted through the readout. A specialist that runs RVMD at 58% and does not trim is a strong signal.
• RVMD Q2 2026 earnings (early August 2026 window): Updated guidance on registrational trial timing for daraxonrasib and the broader RAS-ON program. Cash burn and runway will be the operative numbers.
• BD activity from large-cap oncology acquirers: Any RAS-pathway licensing deal from Lilly, AstraZeneca, or Merck KGaA over the next two quarters becomes a forward indicator of strategic interest. The smart-money signal feed aggregates the broader oncology rotation.

Revolution Medicines is one of the cleanest case studies of how institutional ownership concentration translates a clinical readout into share-price torque. A 58% portfolio weighting from a specialist is not a coincidence — it is a thesis being built around a single mechanism, validated by a single trial. The Q1 13F deadline is the next data point that will tell us whether the funds that made the bet stayed in the position through the catalyst or rotated into the second-derivative names. The full list of RVMD institutional holders is publicly viewable. SEC documentation supporting the Nextech and Paradigm holdings is available via EDGAR's filings page.